摘要
51例原发性高脂血症患者,其血清总胆固醇(TC)≥5.72mmol/L(220mg%)及/或甘油三酯(TG)≥1.65mmol/L(150mg%)。治疗组36例,服诺衡(gemfibrozil)600mg,每天两次,共4周。对照组15例,不用任何血脂调节剂。治疗组服用诺衡4周后,血清TC、TG较服药前明显降低,高密度脂蛋白胆固醇(HDL-C)明显上升,同时伴有血清6-酮-前列腺素F_(1a)(6-Keto-PGF_(1a))及血浆纤维蛋白自然溶解活性(FA)明显上升,而血清血栓素B_2(TXB_2)及血浆纤维蛋白原(Fg)明显下降。对照组各项指标自始至4周末均无明显变化。
Fifty one primary hyperlipidemic patients with serum TC≥220mg% and/or TG≥150mg% were selected from part Ⅰ and were divided into two groups, 36 as treatment group and 15 as control. Gemfibrozil 600mg twice daily was administered in treatment group for 4 weeks while no lipids modulators was given to the control.
Blood samples were drawn before and at the end of the clinical trial in both groups. Parameters were the same as determined in Part Ⅰ. The results were as follows:
(1) There were no significant change of all parameters in the control group;
(2) There were highly significant changes in all paramters in the treatment group after Gemfibrozil therapy for 4 weeks. Serum TC and TG decreased; HDL-C increased; while serum 6-Keto-PGF(?) and FA increased, TXB_2 and Fg decreased.
出处
《中国循环杂志》
CSCD
1989年第4期314-316,392,共4页
Chinese Circulation Journal
